线粒体功能障碍在CKD相关血管钙化中的作用:从机制到治疗
本文综述线粒体功能障碍通过线粒体生物发生、动力学、线粒体自噬、代谢重编程及线粒体相关氧化应激和衰老等多机制加速血管平滑肌细胞成骨分化与血管钙化,为CKD患者血管钙化的临床治疗提供新见解。
要点
- 线粒体功能障碍通过多种机制加速VSMCs成骨分化与血管钙化
- 线粒体生物发生、动力学、自噬及代谢重编程参与CKD血管钙化
- 线粒体相关氧化应激与衰老在血管钙化中起重要作用
核心结论
- 线粒体功能障碍通过多种机制加速血管平滑肌细胞成骨分化与血管钙化,靶向线粒体可能改善CKD患者血管钙化相关不良临床结局。
研究设计与样本
- 本文为综述,总结线粒体生物发生、线粒体动力学、线粒体自噬、代谢重编程及线粒体相关氧化应激和衰老在CKD患者血管钙化中的作用。
主要发现
- 血管平滑肌细胞向成骨表型转分化是血管钙化的主要假设原因。
- 线粒体功能障碍通过多种机制加速血管平滑肌细胞成骨分化与血管钙化。
- 线粒体生物发生、动力学、线粒体自噬、代谢重编程及线粒体相关氧化应激和衰老均参与CKD血管钙化。
临床怎么用
- 阐明血管平滑肌细胞成骨分化与线粒体功能障碍的关系可能有助于改善CKD患者血管钙化相关不良临床结局。
- 综述为血管钙化的临床治疗提供新见解,但目前尚无有效临床治疗方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vascular calcification (VC) is a common complication of chronic kidney disease (CKD) and is closely associated with cardiovascular events. The transdifferentiation of vascular smooth muscles (VSMCs) into an osteogenic phenotype is hypothesized to be the primary cause underlying VC. However, there is currently no effective clinical treatment for VC. Growing evidence suggests that mitochondrial dysfunction accelerates the osteogenic differentiation of VSMCs and VC via multiple mechanisms. Therefore, elucidating the relationship between the osteogenic differentiation of VSMCs and mitochondrial dysfunction may assist in improving VC-related adverse clinical outcomes in patients with CKD. This review aimed to summarize the role of mitochondrial biogenesis, mitochondrial dynamics, mitophagy, and metabolic reprogramming, as well as mitochondria-associated oxidative stress (OS) and senescence in VC in patients with CKD to offer valuable insights into the clinical treatment of VC.
引用
- Huang J, Hao J, Wang P, et al. The Role of Mitochondrial Dysfunction in CKD-Related Vascular Calcification: From Mechanisms to Therapeutics. Kidney Int Rep. 2024. PMID: 39291213. doi:10.1016/j.ekir.2024.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。